DEF: Marker Therapeutics Sets Date for 2025 Annual Stockholders Meeting

Marker Therapeutics announces its Annual Meeting of Stockholders to be held virtually on June 6, 2025, to vote on director elections, executive compensation, and auditor ratification.

Summary

• Marker Therapeutics will hold its Annual Meeting of Stockholders virtually on June 6, 2025, at 10:00 a.m. Eastern Time.
• Stockholders of record as of April 10, 2025, are eligible to vote.
• The meeting will address the election of four directors, an advisory vote on executive compensation, and the ratification of Marcum LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The Board of Directors recommends voting in favor of all proposals.
• Stockholders can register for the virtual meeting until 11:59 p.m. Eastern Time on June 5, 2025.
• The company intends to mail these proxy materials on or about April 24, 2025.
• As of April 10, 2025, there were 11,314,835 shares of common stock outstanding and entitled to vote.

Sentiment

Score: 7

Explanation: The document is neutral in tone, providing factual information about the upcoming Annual Meeting and proposals for stockholder vote. It reflects standard corporate communication practices.

Positives

• The company is providing a virtual meeting option to allow for greater stockholder participation.
• The Board of Directors is actively recommending votes on key proposals.
• The company has a process in place for stockholders to communicate with the Board.

Future Outlook

The document outlines the agenda and procedures for the upcoming Annual Meeting, focusing on corporate governance matters and providing stockholders with the opportunity to vote on key decisions.

Management Comments

• You are cordially invited to attend the Annual Meeting of Stockholders of Marker Therapeutics, Inc.
• Whether or not you expect to attend the meeting, please complete, date, sign and return the enclosed proxy, or vote over the telephone or the internet as instructed in these materials, as promptly as possible in order to ensure your representation at the meeting.

Industry Context

This proxy statement is a standard communication for publicly traded companies, ensuring transparency and providing stockholders with the information needed to make informed decisions regarding the company's direction and governance.

Comparison to Industry Standards

• The proxy statement adheres to SEC regulations and Nasdaq listing standards, ensuring compliance with industry norms for corporate governance and disclosure.
• The virtual meeting format aligns with a growing trend among public companies to enhance accessibility and participation for stockholders.
• The proposals for director elections, executive compensation, and auditor ratification are typical agenda items for annual stockholder meetings of publicly traded companies.

Management Changes

Related Party Transactions

• In 2023, Marker Therapeutics purchased $277,000 of cell culture devices from Wilson Wolf Manufacturing Corporation, where John Wilson, a former member of Marker's board of directors, is the CEO.
• On June 26, 2023, Marker Therapeutics completed a transaction with Cell Ready, LLC, owned by former director John Wilson, selling manufacturing facilities and related assets for $19.0 million.
• In 2023, Marker Therapeutics paid approximately $1.3M to Cell Ready for outsourced product development and manufacturing services.
• In 2024, Marker Therapeutics paid approximately $5.5M to Cell Ready for outsourced product development and manufacturing services.
• On March 27, 2025, Marker Therapeutics mutually agreed with Cell Ready to terminate the MSA and paid Cell Ready approximately $453,000.
• Until June 2023, Marker Therapeutics was party to a services agreement with AlloVir, Inc., where Juan Vera, Marker's CEO, served on the board of directors.

Stakeholder Impact

• Stockholders are provided with the opportunity to vote on key corporate governance matters.
• Executive officers and directors are subject to compensation policies and potential severance arrangements.
• The company's relationships with related parties, such as Wilson Wolf Manufacturing Corporation and Cell Ready LLC, may impact suppliers and customers.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• Stockholders who wish to attend the virtual meeting must register by June 5, 2025.
• The company will announce preliminary voting results at the Annual Meeting and file a Form 8-K with final results.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Executive Compensation, Director Election, Auditor Ratification, Virtual Meeting, Marker Therapeutics